| __timestamp | CRISPR Therapeutics AG | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 855506000 |
| Thursday, January 1, 2015 | 12573000 | 996170000 |
| Friday, January 1, 2016 | 42238000 | 1047690000 |
| Sunday, January 1, 2017 | 69800000 | 1324625000 |
| Monday, January 1, 2018 | 113773000 | 1416476000 |
| Tuesday, January 1, 2019 | 179362000 | 1754540000 |
| Wednesday, January 1, 2020 | 266946000 | 1829537000 |
| Friday, January 1, 2021 | 438633000 | 3051100000 |
| Saturday, January 1, 2022 | 461645000 | 2540300000 |
| Sunday, January 1, 2023 | 387332000 | 3162900000 |
| Monday, January 1, 2024 | 320653000 | 3630300000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG have demonstrated contrasting approaches to R&D investment.
Vertex Pharmaceuticals, a leader in the field, has consistently increased its R&D spending, peaking at approximately $3.16 billion in 2023. This represents a nearly fourfold increase from 2014, underscoring their dedication to pioneering treatments. In contrast, CRISPR Therapeutics, a younger player in the market, has shown a remarkable growth trajectory, with R&D expenses rising from a modest $1.5 million in 2014 to around $387 million in 2023. This growth highlights their aggressive push to innovate in the gene-editing space.
These trends reflect the broader industry dynamics, where established firms and emerging disruptors alike are investing heavily to stay at the forefront of medical breakthroughs.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
R&D Insights: How Vertex Pharmaceuticals Incorporated and Viatris Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Vertex Pharmaceuticals Incorporated and Novavax, Inc.
Ascendis Pharma A/S vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CRISPR Therapeutics AG
Analyzing R&D Budgets: Verona Pharma plc vs CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.
CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending